达格列净对心血管系统保护机制的研究进展
Research Progress on the Protective Mechanism of Dapagliflozin on Cardiovascular System
DOI: 10.12677/ACM.2023.13122857, PDF,   
作者: 米 颖, 李 斯*：唐山市工人医院心内四科，河北 唐山
关键词: 达格列净；心血管疾病；保护机制；综述；Dapagliflozin； Cardiovascular Disease； Protection Mechanisms； Overviews
摘要: 达格列净作为钠–葡萄糖共转运体2抑制剂的代表药物之一，于2017年在中国上市。该药通过独特的降糖机制而发挥作用，除了降低血糖水平外，还具有降脂、降压等多方面的益处。已有研究证实在射血分数轻度下降和保留型患者中应用达格列净可降低心血管死亡、因心衰住院或心衰紧急就诊风险，这为心血管保护作用提供了有力的支持。本文就达格列净对心血管系统保护机制研究进展做一综述。
Abstract: Dapagliflozin, one of the representative drugs of sodium-glucose cotransporter 2 inhibitors, was launched in China in 2017. The drug works through a unique glucose-lowering mechanism, and in addition to lowering blood glucose levels, it also has multiple benefits such as lipid-lowering and blood pressure-lowering. Dapagliflozin has been shown to reduce the risk of cardiovascular death, hospitalization for heart failure or emergency heart failure visits in patients with mildly reduced and preserved ejection fraction, which provides strong support for the cardiovascular protective ef-fects. In this article, we present a review of the progress in the study of the protective mechanism of dapagliflozin on the cardiovascular system.
文章引用：米颖, 李斯. 达格列净对心血管系统保护机制的研究进展[J]. 临床医学进展, 2023, 13(12): 20297-20304. https://doi.org/10.12677/ACM.2023.13122857

参考文献

[1] World Heart Federation (2023) World Heart Report 2023: Confronting the World’s Number One Killer. Geneva, Swit-zerland.
[2] Hong, T., Yan, Z., Li, L., et al. (2022) The Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in China: Results from the Cross-Sectional CAPTURE Study. Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders, 13, 969-981. [Google Scholar] [CrossRef] [PubMed]
[3] Wong, N.D. and Sattar, N. (2023) Cardiovascular Risk in Dia-betes Mellitus: Epidemiology, Assessment and Prevention. Nature Reviews Cardiology, 20, 685-695. [Google Scholar] [CrossRef] [PubMed]
[4] 葛均波, 翁建平, 曾强. 2型糖尿病患者泛血管疾病风险评估与管理中国专家共识(2022版) [J]. 中国循环杂志, 2022, 37(10): 974-990.
[5] Norton, L., Shannon, C.E., Fourcaudot, M., et al. (2017) Sodium-Glucose Co-Transporter (SGLT) and Glucose Transporter (GLUT) Expression in the Kidney of Type 2 Diabetic Subjects. Diabetes, Obesity and Metabolism, 19, 1322- 1326. [Google Scholar] [CrossRef] [PubMed]
[6] Zinman, B., Wanner, C., Lachin, J.M., et al. (2015) Empagliflozin, Cardi-ovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine, 373, 2117-2128. [Google Scholar] [CrossRef] 
[7] Neal, B., Perkovic, V. and Matthews, D.R. (2017) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine, 377, 644-657. [Google Scholar] [CrossRef] 
[8] Solomon, S.D., McMurray, J.J.V., Claggett, B., et al. (2022) Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medi-cine, 387, 1089-1098. [Google Scholar] [CrossRef] 
[9] 董松涛, 董占军. 钠-葡萄糖共转运蛋白2抑制剂作用机制及临床应用研究进展[J]. 国际药学研究杂志, 2017, 44(9): 828-834.
[10] Yang, L., Li, H., Li, H., et al. (2013) Pharmaco-kinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects. Clinical Therapeutics, 35, 1211-1222.e2. [Google Scholar] [CrossRef] [PubMed]
[11] 朱路, 李华荣. 达格列净: 中国的首个SGLT2抑制剂[J]. 实用药物与临床, 2017, 20(11): 1344-1347.
[12] Anand, S., Dagenais, G., Mohan, V., et al. (2012) Glucose Levels Are Associated with Cardiovascular Disease and Death in an International Cohort of Normal Glycaemic and Dysglycae-mic Men and Women: The EpiDREAM Cohort Study. European Journal of Preventive Cardiology, 19, 755-764. [Google Scholar] [CrossRef] [PubMed]
[13] Fox, C.S., Golden, S.H., Anderson, C., et al. (2015) Update on Prevention of Cardiovascular Disease in Adults with Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement from the American Heart Association and the American Diabetes Association. Diabetes Care, 38, 1777-1803. [Google Scholar] [CrossRef] [PubMed]
[14] Wiviott, S.D., Raz, I., Bonaca, M.P., et al. (2019) Dapagliflozin and Car-diovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 380, 347-357. [Google Scholar] [CrossRef] 
[15] Tsapas, A., Karagiannis, T., Kakotrichi, P., et al. (2021) Compara-tive Efficacy of Glucose-Lowering Medications on Body Weight and Blood Pressure in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes, Obesity & Metabolism, 23, 2116-2124. [Google Scholar] [CrossRef] [PubMed]
[16] 戴日新, 刘露佳, 杨锡恒, 等. 达格列净在合并2型糖尿病的射血分数中间值心力衰竭患者中的研究[J]. 实用医学杂志, 2020, 36(18): 2505-2509.
[17] Bertero, E., Prates, Roma, L., Ameri, P., et al. (2018) Cardiac Effects of SGLT2 Inhibitors: The Sodium Hypothesis. Cardiovascular Research, 114, 12-18. [Google Scholar] [CrossRef] [PubMed]
[18] McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., et al. (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine, 381, 1995-2008. [Google Scholar] [CrossRef] 
[19] DeFronzo, R.A., Norton, L. and Abdul-Ghani, M. (2017) Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibition. Nature Reviews Nephrology, 13, 11-26. [Google Scholar] [CrossRef] [PubMed]
[20] Shi, Y., Si, Y., Fu, R., et al. (2022) Efficacy and Safety of SGLT-2i in Overweight/Obese, Non-Diabetic Individuals: A Meta-Analysis of Randomized Controlled Trials. Endokrynologia Polska, 73, 71-80. [Google Scholar] [CrossRef] 
[21] Tsao, C.W., Aday, A.W., Almarzooq, Z.I., et al. (2023) Heart Disease and Stroke Statistics—2023 Update: A Report from the American Heart Association. Circulation, 147, e93-e621. [Google Scholar] [CrossRef] 
[22] Warraich, H.J., Kitzman, D.W., Whellan, D.J., et al. (2018) Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults ≥ 60 Years with Acute Decompensated Heart Failure with Preserved versus Reduced Ejection Fraction: Insights from the REHAB-HF Trial. Circulation: Heart Failure, 11, e005254. [Google Scholar] [CrossRef] 
[23] Ye, Y., Bajaj, M., Yang, H.-C., et al. (2017) SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the De-velopment of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Sax-agliptin, a DPP4 Inhibitor. Cardiovascular Drugs and Therapy, 31, 119-132. [Google Scholar] [CrossRef] [PubMed]
[24] Shi, L., Zhu, D., Wang, S., et al. (2019) Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload. American Journal of Hypertension, 32, 452-459. [Google Scholar] [CrossRef] [PubMed]
[25] Singh, J.S., Fathi, A., Vickneson, K., et al. (2016) Research into the Effect of SGLT2 Inhibition on Left Ventricular Remodelling in Patients with Heart Failure and Diabetes Mellitus (REFORM) Trial Rationale and Design. Cardiovascular Diabetology, 15, Article No. 97. [Google Scholar] [CrossRef] [PubMed]
[26] McDonagh, T.A., Metra, M., Adamo, M., et al. (2023) 2023 Fo-cused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Europe-an Heart Journal, 44, 3627-3639. [Google Scholar] [CrossRef] [PubMed]
[27] 方岩, 张唯薇, 蒋梦婷, 等. 达格列净改善糖尿病动脉粥样硬化模型小鼠斑块的作用机制[J]. 解放军医学院学报, 2022, 43(2): 186-192+198.
[28] Chen, Y.C., Jandeleit-Dahm, K. and Peter, K. (2022) Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes-Induced Atherosclerotic Plaque Instability. Journal of the American Heart Association, 11, e022761. [Google Scholar] [CrossRef] 
[29] Xin, Y., Guo, Y., Li, Y., et al. (2019) Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus: A Systematic Review with an Indirect Comparison Meta-Analysis. Saudi Journal of Biological Sciences, 26, 421-426. [Google Scholar] [CrossRef] [PubMed]
[30] Chino, Y., Samukawa, Y., Sakai, S., et al. (2014) SGLT2 Inhibitor Lowers Serum Uric Acid through Alteration of Uric Acid Transport Activity in Renal Tubule by Increased Glycosuria. Biopharmaceutics & Drug Disposition, 35, 391-404. [Google Scholar] [CrossRef] [PubMed]
[31] Li, F.F., Gao, G., Li, Q., et al. (2016) Influence of Dapagliflozin on Glyce-mic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2016, Article ID: 5347262. [Google Scholar] [CrossRef] [PubMed]
[32] Leng, W., Ouyang, X., Lei, X., et al. (2016) The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/− Mice. Mediators of Inflammation, 2016, Article ID: 6305735. [Google Scholar] [CrossRef] [PubMed]
[33] Uthman, L., Homayr, A., Juni, R.P., et al. (2019) Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells. Cellular Physiology and Biochemistry, 53, 865-886. [Google Scholar] [CrossRef] [PubMed]
[34] Gaspari, T., Spizzo, I., Liu, H., et al. (2018) Dapagliflozin Attenuates Human Vascular Endothelial Cell Activation and Induces Vasorelaxation: A Potential Mechanism for Inhibition of Ath-erogenesis. Diabetes & Vascular Disease Research, 15, 64-73. [Google Scholar] [CrossRef] [PubMed]
[35] Hillis, G.S., Hata, J., Woodward, M., et al. (2012) Resting Heart Rate and the Risk of Microvascular Complications in Patients with Type 2 Diabetes Mellitus. Journal of the American Heart Association, 1, e002832. [Google Scholar] [CrossRef] 
[36] Sattar, N., McLaren, J., Kristensen, S.L., et al. (2016) SGLT2 In-hibition and Cardiovascular Events: Why Did EMPA- REG Outcomes Surprise and What Were the Likely Mechanisms? Diabetologia, 59, 1333-1339. [Google Scholar] [CrossRef] [PubMed]
[37] Matthews, V.B., Elliot, R.H., Rudnicka, C., et al. (2017) Role of the Sympathetic Nervous System in Regulation of the Sodium Glucose Cotransporter 2. Journal of Hypertension, 35, 2059-2068. [Google Scholar] [CrossRef] 
[38] Inzucchi, S.E., Zinman, B., Fitchett, D., et al. (2018) How Does Empagliflozin Reduce Cardiovascular Mortality? Insights from a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 41, 356-363. [Google Scholar] [CrossRef] [PubMed]
[39] Sano, M. and Goto, S. (2019) Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation, 139, 1985-1987. [Google Scholar] [CrossRef] 
[40] Heerspink, H.J., Stefánsson, B.V., Correa-Rotter, R., et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 383, 1436-1446. [Google Scholar] [CrossRef] 
[41] Mosenzon, O., Raz, I., Wiviott, S.D., et al. (2022) Dapagliflozin and Prevention of Kidney Disease among Patients with Type 2 Diabetes: Post Hoc Analyses from the DECLARE-TIMI 58 Trial. Diabetes Care, 45, 2350-2359. [Google Scholar] [CrossRef] [PubMed]
[42] Min, S., Oh, T., Baek, S.-I., et al. (2018) Degree of Ketonaemia and Its Association with Insulin Resistance after Dapagliflozin Treatment in Type 2 Diabetes. Diabetes & Metabolism, 44, 73-76. [Google Scholar] [CrossRef] [PubMed]
[43] 张爱玲, 李朵璐, 周玉冰, 等. 达格列净与2型糖尿病患者泌尿生殖系统感染相关性的Meta分析[J]. 医药导报, 2019, 38(5): 650-655.
[44] Jabbour, S., Seufert, J., Scheen, A., et al. (2018) Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Safety Data from Phase IIb/III Clinical Trials. Diabetes, Obesity and Metabolism, 20, 620-628. [Google Scholar] [CrossRef] [PubMed]
[45] Tang, H., Li, D., Zhang, J., et al. (2017) Sodium-Glucose Co-Transporter-2 Inhibitors and Risk of Adverse Renal Outcomes among Patients with Type 2 Diabetes: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials. Diabetes, Obesity and Metabolism, 19, 1106-1115. [Google Scholar] [CrossRef] [PubMed]
[46] 王育苗, 赵静, 李玥. 达格列净致不良反应文献分析及思考[J]. 中国全科医学, 2020, 23(29): 3649-3654+3666.

为你推荐